Lynch syndrome, historically designated as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), represents the most prevalent inherited hereditary cancer predisposition syndrome, accounting for approximately 2 to 4 percent of all colorectal malignancies^{1, 4}. Inherited in an autosomal dominant pattern with high penetrance, the condition arises from pathogenic germline variants in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes—specifically MLH1, MSH2, MSH6, and PMS2—or from 3-prime deletions of the EPCAM gene leading to epigenetic silencing of MSH2^{1, 2, 7}. Defective MMR mechanisms disable cellular proofreading during DNA replication, causing hypermutability and microsatellite instability (MSI-high) that predisposes affected individuals to a diverse spectrum of aggressive gastrointestinal and extraintestinal neoplasms at an exceptionally early age of onset^{2, 3, 4}.

Etiology & Risk Factors

• Genomic Defect Architecture: Pathogenic variants in MLH1 (chromosome 3p22) and MSH2 (chromosome 2p21) account for roughly 80 to 90 percent of identified molecular diagnoses, presenting with the highest cumulative cancer risks and earlier disease onset^{1, 6}. Mutations in MSH6 (chromosome 2p16) and PMS2 (chromosome 7p22) represent the remainder, often demonstrating a somewhat attenuated penetrance, later age of presentation, and a distinct predominance of endometrial cancer in female carriers^{2, 6}.
• Epigenetic Inactivation via EPCAM Deletions: Deletions involving the 3-prime region of the EPCAM epithelial cell adhesion molecule gene result in transcriptional read-through and subsequent hypermethylation of the adjacent MSH2 promoter, causing functional MSH2 protein deficiency despite an intact wild-type MSH2 gene sequence^{2, 7}.
• Autosomal Dominant Transmission: Each offspring of an affected heterozygous carrier inherits a 50 percent statistical risk of acquiring the pathogenic variant, exhibiting high lifetime penetrance ranging from 40 to 80 percent for colorectal carcinoma depending on the specific mutated gene involved^{5, 6}.
• Extraintestinal Target Organs: Beyond colorectal adenocarcinoma, established risk factors include germline MMR deficiency driving malignant transformation in the endometrium, ovaries, stomach, small bowel, hepatobiliary tract, renal pelvis, ureters, brain (glioblastoma), and sebaceous cutaneous units^{6, 7}.

Pathophysiology

The core pathophysiological driver of Lynch syndrome is the constitutional loss of normal DNA mismatch repair function^{1, 4}. Under physiologic conditions, the MMR protein machinery—functioning as heterodimers of MutL homologues (MLH1 paired with PMS2) and MutS homologues (MSH2 paired with MSH6)—scans newly synthesized DNA strands, detects nucleotide base-base mismatches and insertion-deletion loops generated during replication, excises the erroneous segment, and resynthesizes the correct sequence^{1, 2}. When one allele is constitutionally mutated, a single somatic "second-hit" event inactivating the remaining wild-type allele abrogates MMR activity entirely¹. Consequently, cells acquire a replication-error-repair-deficient phenotype characterized by profound genomic instability, particularly at repetitive mono- and dinucleotide nucleotide tracts known as microsatellites (MSI-H)^{3, 4}. This hypermutable state targets critical microsatellite-containing coding regions of tumour suppressor genes (such as TGF-$\beta$RII, BAX, and ACVR2A), accelerating the adenoma-carcinoma sequence. Unlike sporadic adenomatous polyposis syndromes driven by sequential APC mutations that develop over decades through hundreds of polyps, Lynch syndrome tumorigenesis frequently bypasses the traditional polyp phase, rapidly progressing from normal crypt epithelium to invasive dysplasia and carcinoma within 2 to 3 years via accelerated crypt progenitor transformation. Tumour tissues consistently exhibit dense intraepithelial infiltration of cytotoxic T-lymphocytes, reflecting high neoantigen loads driven by accumulated frameshift mutations^{2, 4}.

Clinical Presentation & Classic Clinical Signs

• History & Cardinal Symptoms:
  • Patients typically present with early-onset malignancies (mean age of colorectal cancer diagnosis at 44 to 61 years compared to 69 years in sporadic cohorts)¹.
  • Gastrointestinal presentations frequently feature right-sided (proximal) colonic localization, manifesting as occult gastrointestinal bleeding, iron-deficiency microcytic anaemia, fatigue, vague right lower quadrant abdominal discomfort, or an insidious palpable abdominal mass^{2, 4}.
  • Female patients commonly present with postmenopausal or premenopausal abnormal uterine bleeding, dysmenorrhea, or pelvic fullness indicative of sentinel Lynch-associated endometrial carcinoma (typically endometrioid adenocarcinoma involving the lower uterine segment)³.
  • Upper gastrointestinal involvement can present with dyspepsia, epigastric pain, or nausea due to gastric or small bowel adenocarcinoma⁷.
• Physical Examination & Named Clinical Signs:
  • Abdominal examination may reveal a palpable mass in the right iliac fossa or ascending colon region corresponding to bulky exophytic caecal or ascending colon tumours⁴.
  • Cutaneous inspection may uncover multiple sebaceous adenomas, sebaceous epitheliomas, sebaceous carcinomas, or eruptive keratoacanthomas pathognomonic of the Muir-Torre syndrome clinical variant⁷.
  • General inspection may reveal pallor of the conjunctivae and nail beds secondary to chronic occult blood loss and iron-deficiency anaemia².

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Staging, Classification & Clinical Scoring Systems

Differential Diagnosis

Management & Treatment Protocol

• Initial Stabilization & Resuscitation:
  • Patients presenting with acute gastrointestinal hemorrhage, symptomatic microcytic anaemia, or acute bowel obstruction require prompt hemodynamic stabilization, intravenous fluid resuscitation, and type-and-crossmatch for packed red blood cells.
  • Urgent surgical or endoscopic decompression is indicated if mechanical large bowel obstruction is present.
• First-Line Medical / Pharmacological Therapy (with exact adult dosing):
  • Chemoprevention: Long-term administration of Acetylsalicylic Acid (Aspirin) at a dosage of 100 mg to 300 mg orally once daily has been demonstrated in clinical trials (CAPP2) to significantly reduce the long-term cumulative incidence of colorectal and other Lynch-associated cancers in mutation carriers⁵.
  • Immunotherapy: For patients who develop advanced or metastatic mismatch repair-deficient (dMMR / MSI-H) malignancies, immune checkpoint inhibitor therapy utilizing monoclonal antibodies such as Pembrolizumab 200 mg intravenously every 3 weeks (or 400 mg intravenously every 6 weeks) or Nivolumab represents first-line systemic therapy, harnessing the dense neoantigen load to achieve durable responses⁴.
• Surgical / Interventional Indications:
  • Colorectal Surveillance: High-resolution screening colonoscopy with indigo carmine or chromoendoscopy every 1 to 2 years, starting between ages 20 to 25 (or 2-5 years prior to the youngest family member's age of diagnosis), with immediate endoscopic resection of all identified adenomatous lesions^{1, 4}.
  • Surgical Resection for CRC: When colorectal cancer is diagnosed, segmental colectomy with en-bloc lymphadenectomy is generally considered, though subtotal or total colectomy with ileorectal anastomosis should be strongly weighed to mitigate the high cumulative risk of metachronous primary colorectal cancers^{1, 4}.
  • Gynecological Prophylaxis: Risk-reducing total hysterectomy and bilateral salpingo-oophorectomy (BSO) is recommended for female Lynch syndrome carriers upon completion of childbearing, typically between ages 40 and 45, to eliminate risks of endometrial and ovarian malignancies³.

Complications & Prognosis

• Oncological Complications: High cumulative lifetime risks of developing metachronous and synchronous malignancies, particularly colorectal cancer (cumulative risk up to 50 to 70 percent) and endometrial cancer (cumulative risk up to 40 to 60 percent in female carriers)^{1, 3, 6}. Additional risks include transitional cell carcinomas of the renal pelvis and ureters, gastric adenocarcinoma, small bowel cancer, and aggressive glioblastomas (Turcot syndrome variant)^{6, 7}.
• Surgical and Obstetric Morbidity: Complications arising from extensive prophylactic resections, including altered bowel habit frequency, pelvic floor dysfunction following total abdominal colectomy, and premature surgical menopause secondary to risk-reducing bilateral salpingo-oophorectomy^{3, 4}.
• Prognosis: Overall prognosis for patients identified through cascade genetic screening and enrolled in rigorous, structured surveillance protocols is remarkably favorable, with survival rates approaching those of the general population. Conversely, unmonitored individuals presenting with advanced, poorly differentiated, or mucinous MMR-deficient tumours face substantial morbidity and mortality, although dMMR tumours intrinsically demonstrate a more favorable stage-adjusted prognosis and resistance to traditional 5-fluorouracil-based adjuvant therapy compared to microsatellite-stable counterparts^{2, 4, 5}.